statistical trend was observed for the relationship between diurnal cortisol levels and positive symptoms (p=0.055). Discussion: The current study is the first to examine the extent to which HPA axis function can predict development of prodromal symptoms in a high-risk cohort. Our finding that more abnormal HPA axis function (i.e., a decreased CAR and higher diurnal cortisol) at age 11-14 years is associated with both prodromal and depression symptoms at age 17-21 has important implications for aetiological theories and for clinical practice.
Background:
The search for biomarkers may prove significant for shortterm identification of UHR individuals (remission/non-remission). On a long-term basis, biomarkers might give the opportunity to delay or prevent psychotic episodes. Disturbances of the neurotransmitters glutamate and GABA have long been suspected to be involved in the pathophysiology of psychosis. These disorders have also found been found in people at UHR, making it a promising area for early detection. Cognitive deficits in schizophrenia are present prior to the onset of psychosis, and may be linked to perturbed glutamate and GABA function. Data suggest that this link is already present in UHR states. Methods: Participants: UHR individuals who meet the CAARMS criteria recruited from Mental Health Services in the Capital Region of Denmark and matching healthy controls. Examinations: 1H-MRS of the ACC and thalamus. Diagnostic and psychopathological tests: CAARMS, SCID, SOFAS, PSP, Cornblatt, SANS, BPRS, MADRS, YMRS, CGI, PAS, SPI-A, AQoL Cognitive tests as part of collaborative studies. Results: So far 116 UHR individuals and 42 healthy controls have been scanned (December 2017) Very early preliminary analysis of the baseline data finds no significant difference in glutamate levels (in ACC and thalamus) in UHR patients compared to matched healthy controls. Baseline data remains to be analysed in relation to relevant subgroups of patients e.g. based on clinical outcome. GABA analysis and analysis of follow-up data are also yet to be performed. Data will be ready for the meeting, and will be presented. Discussion: More studies are needed in this field, since results so far have been diverging. Baseline data remains to be analysed in relation to relevant subgroups of patients e.g. based on clinical outcome. GABA analysis and analysis of follow-up data are also yet to be performed. Glutamate data will be presented at the meeting. 7 ± 8.9 -26.9 ± 7.9 (t=3.362)], Blunted Affect subscale [6.9 ± 5.0 -5.9 ± 4.7 (t=2.489)], and almost significant (p<0.069) in CAINS-EXP and BNSS total score. No significant changes in BMI, waist circumference, smoking or antipsychotic equivalent doses were detected, but they were also considered in regression analyses. A higher percentage of hemolysis at baseline, with a decrease in equivalent doses of antipsychotics, both significantly predict an improvement in scores of PANSS-N (R2=0.140, F=7.166), BNSS (R2=0.246, F=6.193 ) and CAINS-EXP (R2=0.186, F=5.259). Discussion: Lower concentrations of LPO were related to greater severity of negative symptoms as avolition and blunted affect (inner world). Longitudinal analyses showed that higher % of hemolysis at baseline predict an improvement of negative dimension at 1-year follow-up. From our results, we hypothesize that there is an inverse relationship between oxidative stress and negative dimension in stable patients with schizophrenia during the first ten years of illness. Background: In schizotypy, a factor structure similar to the one observed in schizophrenia has been unraveled, being the positive and negative the most consistently replicated dimensions. Despite this fact, most of the studies on brain volume patterns in schizotypy consider it as an unitary rather than a multidimensional construct. Hence, based on previous results showing that schizophrenia and schizotypal personality traits share common
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